Opendata, web and dolomites

CONQR SIGNED

Translation and Commercialization of a QSOX1-inhibitory Antibody Targeting the Tumor Microenvironment in Breast Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CONQR project word cloud

Explore the words cloud of the CONQR project. It provides you a very rough idea of what is the project "CONQR" about.

global    deaths    matrix    metastasis    significantly    penetration    reduce    stress    worldwide    societal    inhibitory    stiffening    inhibition    continuing    metastases    mastectomy    physical    90    adenocarcinomas    model    women    adhesion    licensing    commercialization    therapies    recommended    preventive    revolutionizing    therapeutics    cell    therapeutic    relapse    radiation    remodeling    migration    patient    brca1    efficacy    aggressive    preclinical    mice    imposes    gene    standard    discoveries    experiments    secreted    indications    found    discovery    market    benefit    tumor    monoclonal    counteracts    promise    mutations    prevents    pancreatic    unquantifiable    oophorectomy    chemotherapy    plan    enzyme    majority    triple    position    primary    families    entering    conqr    psychological    risk    treatment    made    oncology    breast    intended    reagent    young    lung    cancers    added    applicable    points    antibody    qsox1    cancer    negative    inhibitor    ecm    explore    perform    regimen    demand    drug    extracellular    tnbc    mothers    outcome    agent    chemotherapies    showed   

Project "CONQR" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 149˙998 €
 EC max contribution 149˙998 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 149˙998.00

Map

 Project objective

The high number of cancer cases worldwide points to the large global demand for therapeutics for adenocarcinomas (the majority of lung, breast, and pancreatic cancers). Cancer metastases cause more than 90% of cancer patient deaths. There is thus great need to develop more targeted cancer therapies, as well as therapies that enhance the delivery and penetration of chemotherapies to reduce side effects and increase efficacy. A specific societal need is improved therapies for triple-negative breast cancer (TNBC), to which the targeted therapies developed for other breast cancers are not applicable. TNBC treatment, particularly for women with BRCA1 gene mutations, typically involves aggressive chemotherapy, mastectomy, and radiation treatment, with preventive oophorectomy also recommended. The physical and psychological impact of this regimen on young mothers and their families is unquantifiable, and the risk of relapse imposes continuing psychological stress.

We have made a revolutionizing discovery that significantly controlled cancer cell adhesion, cell migration, primary tumor growth, and metastasis. We found that inhibition of the secreted enzyme QSOX1 by a monoclonal antibody inhibitor counteracts extracellular matrix ECM matrix stiffening and prevents tumor cell adhesion and migration. The QSOX1 inhibitor showed an added benefit in controlling primary tumor growth and metastasis when provided together with standard chemotherapy in a TNBC model in mice. The antibody drug we are developing based on these exciting discoveries has great promise for commercialization as a new therapeutic agent for TNBC and for other oncology indications.

The goal of the CONQR project is to perform key preclinical experiments and explore market entering opportunities for commercialization of a novel QSOX1-inhibitory reagent against ECM remodeling in cancer. The intended outcome will be a development and commercialization plan to best position the product for out-licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONQR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONQR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

PGErepro (2019)

How to break Mendel’s laws? The role of sexual conflict in the evolution of unusual transmission genetics

Read More